Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

NCT00002524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2012-07-30

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.

Conditions

Interventions

BIOLOGICAL

Bleomycin Sulfate

BIOLOGICAL

Filgrastim

DRUG

Cisplatin

DRUG

Cytarabine

DRUG

Doxorubicin Hydrochloride (DOX)

DRUG

Etoposide

DRUG

Ifosfamide

DRUG

Leucovorin calcium

DRUG

Methotrexate

DRUG

Methylprednisolone

DRUG

Pentamidine

DRUG

Prednisone

DRUG

Vincristine Sulfate

DRUG

Zidovudine (AZT)

RADIATION

Radiation Therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Peter W. McLaughlin, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-06-30
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002524 on ClinicalTrials.gov